EN DE

Medipower -M (MDPR) Fair Value & Analysis

Real Estate · Il · Market cap 263M ILA · ISIN CY0100361019

MM Medipower -M MDPR · TA
Price5.14 ILA
Fair Value4.48 ILA
Upside-12.9%
Quality58/100
Watch Medipower -M for free, get notified when fair value or trend changes. Watch for free

Strengths

✓Highly profitable · 22.3% net margin
✓Moderate debt · generates free cash flow
✓Wide moat 65/100

Risks

!Trades 15% ABOVE our fair value of 4.48 ILA
!Mixed Growth (revenue 5y +13.3 %/yr)
!Mixed vs. peers (7/14)
!Evidence only medium, so the estimate is less certain
Mixed Growth (revenue 5y +13.3 %/yr)
Highly profitable · 22.3% net margin
Moderate debt · generates free cash flow
Mixed vs. peers (7/14)
Wide moat 65/100
Evidence: Medium Range 3.36 ILA – 5.60 ILA Share as image

Fair value as of: Aug 27, 2026

From 16 valuation models · updated yesterday

Share price −18.5% over the past month.

A solid business, but trading 15% above our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Track Medipower -M and get told automatically when its fair value or trend turns, plus fair value for all 35,000+ stocks. 14 days of Pro free, no card. Track it free

What matters now

  • Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
  • As a real-estate business, asset- and dividend-based methods carry more weight here than a standard DCF.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

8.52 ILA 4.20 ILA Fair Value 4.48 ILA May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.

How to read this chart

60‑month range 4.20 ILA – 8.52 ILA · fair‑value band 3.36 ILA – 5.60 ILA · the 5.14 ILA price screens above the 4.48 ILA fair value. Dashed = 300-day average. As of Aug 27, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Medipower -M (MDPR) currently trades at 5.14 ILA, while our model-based Fair Value estimate is 4.48 ILA, implying the stock looks roughly 12.9% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Real Estate sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Medipower -M generated revenue of 43.0M ILA at a net margin of 22.3%. Revenue grew 19.8% year over year. It earns a return on equity of 6.8%. Net debt stands at 277M ILA. Fundamentals as of Aug 27, 2026

Our scenario range runs from 3.36 ILA (bear case) to 5.60 ILA (bull case); at 5.14 ILA, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Real Estate peers we cover trades at -25% fair-value upside, at -13%, MDPR screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 3.46 ILA 6.69 ILA 11.77 ILA 80
Residual Income 2.30 ILA 2.46 ILA 2.75 ILA 76
Rev-Margin DCF 4.21 ILA 8.39 ILA 17.14 ILA 74
All 16 models by family
DCF Models
FCF DCF 3.76 ILA 5.93 ILA 12.44 ILA 38
5Y Revenue Exit 3.71 ILA 7.22 ILA 14.56 ILA 39
5Y EBITDA Exit 5.18 ILA 10.18 ILA 19.99 ILA 41
10Y Revenue Exit 3.59 ILA 9.08 ILA 12.60 ILA 36
10Y EBITDA Exit 4.73 ILA 11.96 ILA 24.64 ILA 37
Dividend Discount
Gordon GGM 0.2300 ILA 0.4100 ILA 0.5600 ILA 70
DDM Multi-Stage 0.2300 ILA 0.3700 ILA 0.4400 ILA 61
Multiples
P/S Multiple 3.36 ILA 4.48 ILA 5.60 ILA 58
P/B Multiple 3.36 ILA 4.48 ILA 5.60 ILA 55
EV/EBIT 7.72 ILA 10.62 ILA 13.52 ILA 53
EV/EBITDA 5.74 ILA 7.98 ILA 10.22 ILA 54
EV/Revenue 3.31 ILA 5.15 ILA 6.99 ILA 43
Asset-Based
NCAV (Graham) 1.43 ILA 1.92 ILA 2.86 ILA 50
Growth DCF
Growth DCF 3.46 ILA 6.69 ILA 11.77 ILA 80
Rev-Margin DCF 4.21 ILA 8.39 ILA 17.14 ILA 74
Economic Profit
Residual Income 2.30 ILA 2.46 ILA 2.75 ILA 76

Widest divergence: DCF Models (9.08 ILA) versus Dividend Discount (0.3700 ILA). Highest evidence: Growth DCF (80).

Notify me when MDPR reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 42.5
P/S ratio 12.8 P/E × margin
EPS (TTM) 0.1210 ILA price ÷ EPS = P/E 42.5
Net margin 30.1% FY2025
Return on equity 6.8% TTM
Return on assets (EBIT) 5.3% avg 5y
More key figures
Profitability
Operating margin 56.1% TTM
Growth
Revenue (TTM) 43.0M ILA TTM
Revenue growth (YoY) +19.8% 3y avg +6.1%
EPS growth (YoY) +149%
Balance sheet & cash flow
Free cash flow 17.8M ILA FY2025
Net debt 277M ILA FY2025 · ≈ 15.6 yrs of FCF

Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 58/100

Of which business quality 56 · Market factors (momentum, volatility) 34

Profitability 37
Margins and returns on capital today
Quality Growth 32
Are margins and returns improving?
Cashflow 89
Earnings quality: real cash, not paper profit
Fin. Strength 37
Balance sheet, leverage, solvency risk
Investment 70
Disciplined investing over empire-building
Low Volatility 81
Calm price path (market factor)
Momentum 21
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 81
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Medipower (Overseas) Public Co. Limited, together with its subsidiaries, operates as a commercial real estate company in the United States, Canada, and Bulgaria. It engages in the acquisition, rental, redevelopment, operation, and management of commercial income-generating real estate, primarily retail properties.

Full company description

Medipower (Overseas) Public Co. Limited, together with its subsidiaries, operates as a commercial real estate company in the United States, Canada, and Bulgaria. It engages in the acquisition, rental, redevelopment, operation, and management of commercial income-generating real estate, primarily retail properties. The company was incorporated in 2001 and is based in Nicosia, Cyprus.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Medipower -M reported revenue of 44.8M ILA in FY2025 versus 30.8M ILA in FY2021, a compound +9.8%/yr. Reported net income was 13.5M ILA in FY2025, compounding +10.0%/yr from FY2021.

Growth Quality 86/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
44.8M ILS
Latest YoY
+14.4%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.1%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.3%
Avg. revenue growth/yr (19Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+8.5%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
+19.6% (19.6 + 0.0)
Revenue +9.8%/yr
FY21 30.8M ILA
FY22 37.5M ILA
FY23 38.6M ILA
FY24 39.2M ILA
FY25 44.8M ILA
Net income +10.0%/yr
FY21 9.2M ILA
FY22 1.3M ILA
FY23 8.0M ILA
FY24 10.2M ILA
FY25 13.5M ILA

MDPR screens 13% overvalued. Compare with CBRE Group →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medipower -M · Fair Value
4.48 ILA −13%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Medipower -M Fair Value". https://www.fairvalue-calculator.com/stock/MDPR

Peer Group

Real Estate Services · 547 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 59 · Above median
Fair Value upside −13% · Below median
Return on equity (TTM) 7% · Above median
Return on assets 3% · Above median
Net margin (TTM) 22% · Above median
Operating margin (TTM) 56% · Top 25%
Revenue growth 20% · Top 25%
Dividend yield (TTM) 0.5% · Bottom 25%
Debt / equity 0.85× · Higher than median

Valuation Multiples vs Real Estate Services median · lower = cheaper

P/E (TTM) 42.5× · Pricier than 75% of peers
P/B 1.80× · Pricier than 75% of peers
P/S (TTM) 6.12× · Pricier than 75% of peers
P/FCF 5.0× · Pricier than median
EV/EBITDA 8.5× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE16 · sector 33
FUTURE99 · sector 10
PAST27 · sector 17
HEALTH57 · sector 84
DIVIDEND10 · sector 59

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Real Estate Services stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).

Stock Price Fair Value vs Fair Value
CBRE Group CBRE $147.40 $69.47 -53%
Vonovia SE VNA €19.95 €36.67 +84%
Cellnex Telecom, S.A CLNX €27.47 €25.46 -7%
KE Holdings BEKE $17.42 $6.57 -62%
Jones Lang LaSalle Incorporated JLL $386.08 $290.25 -25%
Swire Properties Limited 1972 HK$24.84 HK$5.12 -79%
CoStar Group CSGP $32.14 $4.64 -86%
China Resources Mixc Lifestyle Services Limited 1209 HK$39.84 HK$34.95 -12%
CapitaLand Investment Limited 9CI 2.73 SGD 0.4900 SGD -82%
Plaza S.A MALLPLAZA 3,989 CLP 4,571 CLP +15%

Compare Medipower -M with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Real Estate stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Fama-French 3-Factor Model Calculator Run the Fama-French 3-factor model in seconds: expected return from the market, size and value factors - free, with formula, betas and an example. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Medipower -M (MDPR) overvalued or undervalued?
As of Aug 27, 2026, our model estimates a fair value of 4.48 ILA versus a price of 5.14 ILA, about −13% (overvalued).
What is the fair value of MDPR?
Our model-based fair value for Medipower -M is 4.48 ILA (as of Aug 27, 2026), built from audited fundamentals. The current price: 5.14 ILA.
What is the quality score of MDPR?
Medipower -M has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Medipower -M (MDPR)?
Medipower -M reported trailing-twelve-month revenue of about 43.0M ILS (latest available figure, as of Aug 27, 2026).
What is the net profit margin of MDPR?
The net profit margin of Medipower -M is about 22.3%, meaning it keeps roughly 22.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

Free · no account needed

Watch Medipower -M in the live analysis

One click puts Medipower -M on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.